GB0419159D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number: GB0419159D0
Authority: GB; United Kingdom
Prior art keywords: organic compounds; compounds; organic
Prior art date: 2004-08-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

GBGB0419159.9A

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee

Novartis AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-08-27

Filing date

2004-08-27

Publication date

2004-09-29

2004-08-27 Application filed by Novartis AG filed Critical Novartis AG

2004-08-27 Priority to GBGB0419159.9A priority Critical patent/GB0419159D0/en

2004-09-29 Publication of GB0419159D0 publication Critical patent/GB0419159D0/en

2005-08-26 Priority to PCT/EP2005/009253 priority patent/WO2006021456A1/en

Status Ceased legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

GBGB0419159.9A 2004-08-27 2004-08-27 Organic compounds Ceased GB0419159D0 (en)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
GBGB0419159.9A GB0419159D0 (en)	2004-08-27	2004-08-27	Organic compounds
PCT/EP2005/009253 WO2006021456A1 (en)	2004-08-27	2005-08-26	Combination comprising a staurosporine and a cyp3a4 inhibitor

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0419159.9A GB0419159D0 (en)	2004-08-27	2004-08-27	Organic compounds

Publications (1)

Publication Number	Publication Date
GB0419159D0 true GB0419159D0 (en)	2004-09-29

Family

ID=33104744

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GBGB0419159.9A Ceased GB0419159D0 (en)	2004-08-27	2004-08-27	Organic compounds

Country Status (2)

Country	Link
GB (1)	GB0419159D0 (en)
WO (1)	WO2006021456A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8501792B2 (en)	2008-02-19	2013-08-06	David A. Potter	Treating cancer with desthiazolyl ritonavir
CN102101866A (en) *	2010-11-04	2011-06-22	中国海洋大学	Halogenated derivatives of staurosporine, and preparation method thereof and use thereof
CN103169703B (en) *	2011-12-22	2014-10-08	清华大学深圳研究生院	New application of sertindole drug
WO2024223797A1 (en)	2023-04-28	2024-10-31	Institut National de la Santé et de la Recherche Médicale	Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19744676A1 (en) *	1997-10-10	1999-04-15	Forschungszentrum Borstel Zent	Combination product for cancer therapy
GB9903547D0 (en) *	1999-02-16	1999-04-07	Novartis Ag	Organic compounds
IL161156A0 (en) *	2001-10-30	2004-08-31	Novartis Ag	Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
US20040246627A1 (en) *	2003-06-06	2004-12-09	Durrum Thomas M.	Disc drive pivot bearing assembly
TWI324604B (en) *	2003-06-18	2010-05-11	Novartis Ag	New use of staurosporine derivatives
CA2533861A1 (en) *	2003-08-08	2005-02-17	Novartis Ag	Combinations comprising staurosporines
US20050159404A1 (en) *	2003-09-11	2005-07-21	Ming-Sing Si	Organic compound
WO2005053704A1 (en) *	2003-12-01	2005-06-16	Novartis Ag	Method for predicting drug responsiveness in myeloid neoplasms

2004
- 2004-08-27 GB GBGB0419159.9A patent/GB0419159D0/en not_active Ceased
2005
- 2005-08-26 WO PCT/EP2005/009253 patent/WO2006021456A1/en active Application Filing

Also Published As

Publication number	Publication date
WO2006021456A1 (en)	2006-03-02

Publication	Publication Date	Title
GB0410712D0 (en)	2004-06-16	Organic compounds
GB0409921D0 (en)	2004-06-09	Organic compounds
GB0403038D0 (en)	2004-03-17	Organic compounds
GB0407723D0 (en)	2004-05-12	Organic compounds
GB0405289D0 (en)	2004-04-21	Organic compounds
GB0401334D0 (en)	2004-02-25	Organic compounds
GB0402797D0 (en)	2004-03-10	Organic compounds
GB0404434D0 (en)	2004-03-31	Organic compounds
GB0408078D0 (en)	2004-05-12	Organic compounds
GB0425661D0 (en)	2004-12-22	Organic compounds
GB0403115D0 (en)	2004-03-17	Organic compounds
GB0406515D0 (en)	2004-04-28	Organic compounds
GB0419159D0 (en)	2004-09-29	Organic compounds
GB0403254D0 (en)	2004-03-17	Organic compounds
GB0409236D0 (en)	2004-05-26	Organic compounds
GB0405723D0 (en)	2004-04-21	Organic compounds
GB0406240D0 (en)	2004-04-21	Organic compounds
GB0405034D0 (en)	2004-04-07	Organic compounds
GB0407607D0 (en)	2004-05-05	Organic compounds
GB0407468D0 (en)	2004-05-05	Organic compounds
GB0405898D0 (en)	2004-04-21	Organic compounds
GB0409235D0 (en)	2004-05-26	Organic compounds
GB0410264D0 (en)	2004-06-09	Organic compounds
GB0406738D0 (en)	2004-04-28	Organic compounds
GB0406381D0 (en)	2004-04-21	Organic compounds

Legal Events

Date	Code	Title	Description
2006-12-13	AT	Applications terminated before publication under section 16(1)